Concepts (119)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medication Therapy Management | 3 | 2021 | 12 | 1.310 |
Why?
|
| Antihypertensive Agents | 4 | 2015 | 284 | 1.070 |
Why?
|
| Veterans | 7 | 2023 | 115 | 1.020 |
Why?
|
| Pharmacists | 3 | 2021 | 53 | 1.010 |
Why?
|
| Hypertension | 4 | 2015 | 770 | 0.950 |
Why?
|
| Dementia | 3 | 2010 | 133 | 0.950 |
Why?
|
| Medication Adherence | 2 | 2015 | 165 | 0.770 |
Why?
|
| Spinal Cord Injuries | 4 | 2023 | 60 | 0.760 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2020 | 790 | 0.650 |
Why?
|
| Bacteriuria | 3 | 2021 | 5 | 0.560 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2021 | 592 | 0.500 |
Why?
|
| Nicotinic Acids | 3 | 2013 | 11 | 0.490 |
Why?
|
| Home Care Services | 2 | 2015 | 29 | 0.470 |
Why?
|
| Health Services for the Aged | 2 | 2008 | 17 | 0.410 |
Why?
|
| Blood Pressure | 2 | 2015 | 613 | 0.380 |
Why?
|
| Aged | 9 | 2021 | 6448 | 0.360 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2010 | 63 | 0.360 |
Why?
|
| Hospitals, Veterans | 2 | 2005 | 16 | 0.330 |
Why?
|
| Community Pharmacy Services | 1 | 2008 | 24 | 0.330 |
Why?
|
| Patient Satisfaction | 1 | 2008 | 141 | 0.320 |
Why?
|
| Perception | 1 | 2008 | 183 | 0.300 |
Why?
|
| Thromboembolism | 1 | 2007 | 14 | 0.300 |
Why?
|
| Drug Monitoring | 1 | 2007 | 17 | 0.300 |
Why?
|
| Nonprescription Drugs | 1 | 2006 | 6 | 0.300 |
Why?
|
| Patient Education as Topic | 1 | 2008 | 207 | 0.300 |
Why?
|
| Hemorrhage | 1 | 2007 | 46 | 0.300 |
Why?
|
| Niacin | 1 | 2006 | 23 | 0.290 |
Why?
|
| Delayed-Action Preparations | 1 | 2006 | 57 | 0.290 |
Why?
|
| Warfarin | 1 | 2007 | 59 | 0.280 |
Why?
|
| Anticoagulants | 1 | 2007 | 97 | 0.280 |
Why?
|
| Cognition Disorders | 1 | 2008 | 233 | 0.280 |
Why?
|
| Hypotension, Orthostatic | 1 | 2005 | 2 | 0.270 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2005 | 3 | 0.270 |
Why?
|
| Drug Therapy | 1 | 2005 | 18 | 0.270 |
Why?
|
| Human Experimentation | 1 | 2005 | 12 | 0.260 |
Why?
|
| Humans | 18 | 2023 | 34853 | 0.260 |
Why?
|
| Aged, 80 and over | 5 | 2017 | 2333 | 0.260 |
Why?
|
| Spinal Cord Diseases | 1 | 2023 | 6 | 0.240 |
Why?
|
| Research | 1 | 2005 | 159 | 0.230 |
Why?
|
| Retrospective Studies | 5 | 2023 | 1961 | 0.220 |
Why?
|
| Anti-Bacterial Agents | 3 | 2023 | 355 | 0.210 |
Why?
|
| Hospices | 1 | 2021 | 3 | 0.210 |
Why?
|
| Urinary Tract Infections | 1 | 2021 | 36 | 0.200 |
Why?
|
| Male | 9 | 2017 | 18870 | 0.190 |
Why?
|
| Hypoglycemic Agents | 1 | 2021 | 152 | 0.180 |
Why?
|
| Female | 8 | 2017 | 19873 | 0.180 |
Why?
|
| Calcium Channel Blockers | 2 | 2010 | 56 | 0.170 |
Why?
|
| Physicians | 1 | 2020 | 148 | 0.160 |
Why?
|
| Polypharmacy | 2 | 2008 | 27 | 0.160 |
Why?
|
| Urinalysis | 1 | 2017 | 31 | 0.160 |
Why?
|
| United States | 4 | 2023 | 3894 | 0.140 |
Why?
|
| Pharmaceutical Services | 1 | 2015 | 22 | 0.140 |
Why?
|
| Cohort Studies | 2 | 2009 | 1422 | 0.120 |
Why?
|
| Pilot Projects | 1 | 2015 | 628 | 0.120 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 964 | 0.110 |
Why?
|
| Prevalence | 2 | 2009 | 1425 | 0.110 |
Why?
|
| Treatment Outcome | 1 | 2015 | 1349 | 0.100 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2010 | 8 | 0.090 |
Why?
|
| Health Status Disparities | 1 | 2015 | 583 | 0.090 |
Why?
|
| Memantine | 1 | 2009 | 5 | 0.090 |
Why?
|
| Drug Utilization | 1 | 2009 | 29 | 0.090 |
Why?
|
| Data Collection | 1 | 2010 | 188 | 0.090 |
Why?
|
| Medicare Part D | 1 | 2008 | 7 | 0.090 |
Why?
|
| Income | 1 | 2010 | 135 | 0.090 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2008 | 20 | 0.080 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2009 | 41 | 0.080 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2010 | 243 | 0.080 |
Why?
|
| Databases, Factual | 1 | 2010 | 288 | 0.080 |
Why?
|
| Prescription Drugs | 1 | 2008 | 31 | 0.080 |
Why?
|
| Quality Assurance, Health Care | 1 | 2008 | 55 | 0.080 |
Why?
|
| Educational Status | 1 | 2010 | 295 | 0.080 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2008 | 64 | 0.080 |
Why?
|
| Program Development | 1 | 2008 | 225 | 0.080 |
Why?
|
| Texas | 1 | 2008 | 299 | 0.080 |
Why?
|
| Drug Interactions | 1 | 2007 | 137 | 0.080 |
Why?
|
| International Normalized Ratio | 1 | 2007 | 10 | 0.080 |
Why?
|
| Vitamins | 1 | 2008 | 91 | 0.080 |
Why?
|
| Program Evaluation | 1 | 2008 | 316 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 195 | 0.070 |
Why?
|
| Solubility | 1 | 2006 | 115 | 0.070 |
Why?
|
| Ambulatory Care | 1 | 2007 | 76 | 0.070 |
Why?
|
| Prazosin | 1 | 2005 | 11 | 0.070 |
Why?
|
| Furosemide | 1 | 2005 | 9 | 0.070 |
Why?
|
| Lisinopril | 1 | 2005 | 5 | 0.070 |
Why?
|
| Joint Commission on Accreditation of Healthcare Organizations | 1 | 2005 | 1 | 0.070 |
Why?
|
| Outpatients | 1 | 2005 | 33 | 0.070 |
Why?
|
| Hydrochlorothiazide | 1 | 2005 | 20 | 0.070 |
Why?
|
| Incidence | 1 | 2008 | 882 | 0.070 |
Why?
|
| Antidepressive Agents | 1 | 2005 | 53 | 0.060 |
Why?
|
| Age Factors | 1 | 2008 | 1007 | 0.060 |
Why?
|
| Guideline Adherence | 1 | 2005 | 82 | 0.060 |
Why?
|
| Antipsychotic Agents | 1 | 2005 | 68 | 0.060 |
Why?
|
| Healthcare Disparities | 1 | 2009 | 446 | 0.060 |
Why?
|
| Patient Selection | 1 | 2005 | 154 | 0.060 |
Why?
|
| Palliative Care | 1 | 2021 | 52 | 0.050 |
Why?
|
| Cross-Sectional Studies | 1 | 2008 | 2561 | 0.050 |
Why?
|
| Inpatients | 1 | 2021 | 72 | 0.050 |
Why?
|
| Escherichia coli | 1 | 2023 | 436 | 0.050 |
Why?
|
| Middle Aged | 2 | 2017 | 9642 | 0.050 |
Why?
|
| Risk Factors | 1 | 2008 | 3414 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2013 | 406 | 0.040 |
Why?
|
| Unnecessary Procedures | 1 | 2017 | 9 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 47 | 0.040 |
Why?
|
| Quality of Life | 1 | 2021 | 459 | 0.040 |
Why?
|
| Rats | 2 | 2013 | 3261 | 0.030 |
Why?
|
| Half-Life | 1 | 2013 | 52 | 0.030 |
Why?
|
| Biotransformation | 1 | 2013 | 65 | 0.030 |
Why?
|
| Hydrolysis | 1 | 2013 | 86 | 0.030 |
Why?
|
| Kinetics | 1 | 2013 | 650 | 0.030 |
Why?
|
| Animals | 3 | 2013 | 14307 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2013 | 1534 | 0.020 |
Why?
|
| Reference Standards | 1 | 2008 | 52 | 0.020 |
Why?
|
| Medication Errors | 1 | 2007 | 6 | 0.020 |
Why?
|
| Food-Drug Interactions | 1 | 2007 | 5 | 0.020 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2008 | 94 | 0.020 |
Why?
|
| Drug Stability | 1 | 2008 | 110 | 0.020 |
Why?
|
| Temperature | 1 | 2008 | 275 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2008 | 901 | 0.020 |
Why?
|
| Adult | 1 | 2017 | 11034 | 0.010 |
Why?
|